Ticker

No recent analyst price targets found for NTZ.

Latest News for NTZ

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new…

GlobeNewsWire • Mar 9, 2026
Natuzzi Received Continued Listing Standard Notice From the NYSE

SANTERAMO IN COLLE, Bari, Italy--(BUSINESS WIRE)-- #NATUZZI--Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) announced today that on January 6, 2026 it received notice from the New York Stock Exchange (the “NYSE”) that the Company was no longer in compliance with one of the NYSE's continued listing standards for a listed company (the “NYSE Notice”), because its 30 trading-day average market capitalization…

Business Wire • Feb 5, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for NTZ.

No House trades found for NTZ.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top